Cell Biotech Records KRW 14.6 Billion in Revenue and KRW 3.2 Billion in Operating Profit for Q1 2026

Cell Biotech, the company behind the highly resilient probiotic brand DUOLAC, announced strong growth in both revenue and operating profit for the first quarter of 2026, driven by the global expansion of K-probiotics.

According to its preliminary earnings results for Q1 2026, Cell Biotech recorded revenue of KRW 14.6 billion, operating profit of KRW 3.2 billion, and net profit of KRW 5.4 billion. Compared to the same period last year, revenue increased by 30%, operating profit by 134%, and net profit by 158.6%.

The improved performance was attributed to continued growth in overseas exports and solid domestic sales. In particular, overseas sales saw significant growth during the first quarter, leading the company’s overall earnings increase. Based on its proprietary dual-coating technology, Cell Biotech has significantly enhanced probiotic survivability and continues to strengthen its competitiveness in the global market with strains registered under FDA GRAS (Generally Recognized As Safe).

DUOLAC is currently exported to 55 countries worldwide, including Denmark, the birthplace of probiotics. The company has maintained the No.1 position in Korean probiotic exports for 12 consecutive years, while cumulative exports to Germany and Indonesia have each surpassed USD 30 million. These achievements are regarded as proof of the global competitiveness and brand credibility of K-probiotics beyond simple product sales.

In January this year, DUOLAC achieved a 46.6% market share in Denmark’s pharmacy market, ranking No.1 in local sales. This result is particularly meaningful as a Korean probiotic brand overtook long-standing local brands that had consistently held the top market share since data tracking began.

As part of its global expansion strategy, Cell Biotech continues to participate in major international exhibitions, including Vitafoods Europe 2026, the world’s largest nutraceutical trade show, to accelerate its penetration into overseas markets. The company also established a local sales subsidiary in Denmark, becoming the first Korean company to do so, further strengthening its brand presence in Europe.

A company official stated, “As global demand for K-probiotics continues to grow, DUOLAC’s technological capabilities and product quality are gaining recognition in overseas markets. We will continue to strengthen our global competitiveness through ongoing R&D and expansion of our international network, while fulfilling our mission of globalizing K-probiotics.”